CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to study the drug CNF2024 as a single agent or in
combination with trastuzumab in patients with advanced breast cancer and to:
- find the highest dose of the drug CNF2024 as a single agent or in combination with
trastuzumab that can be given safely
- measure levels of CNF2024 as a single agent or in combination with trastuzumab in blood
- determine if CNF2024 as a single agent or in combination with trastuzumab can stop
breast cancer cells from growing